https://doi.org/10.4081/itjm.2024.1724

A rare case of thrombocytopenia secondary to taking febuxostat

Vol. 18 No. 2 (2024)
Published: 23 April 2024
Febuxostat, thrombocytopenia
Abstract Views: 446
PDF: 322
HTML: 157
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Isabella Di Zio
isabella.dizio@katamail.com
Department of Internal Medicine, San Massimo Hospital, Penne (PE), Italy.
Rodolfo Cisternino
Community hospital, Maria SS Immacolata Hospital, Guardiagrele (CH), Italy.

A new and powerful selective xanthine oxidase inhibitor called febuxostat seems to be well tolerated by all patient populations, even those who are allopurinol-sensitive. Thrombocytopenia is an extremely uncommon side effect. The case of a 63- year-old man who presented with sudden thrombocytopenia and was ultimately linked to febuxostat consumption is described below. The case happened in our department.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

PlumX Metrics

PlumX Metrics  provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Hu M, Tomlinson B. Febuxostat in the management of hyperuricemia and chronic gout: a review. Ther Clin Risk Manag 2008;4:1209-20. DOI: https://doi.org/10.2147/TCRM.S3310
Okamoto K, Eger BT, Nishino T, et al. An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848-55. DOI: https://doi.org/10.1074/jbc.M208307200
Takano Y, Hase-Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/ xanthine dehydrogenase. Life Sci 2005;76:1835-47. DOI: https://doi.org/10.1016/j.lfs.2004.10.031
Okamoto K, Nishino T. Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051. J Nippon Med Sch 2008;75:2-3. DOI: https://doi.org/10.1272/jnms.75.2
Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents. Eur J Pharmacol 1993;241:183-8. DOI: https://doi.org/10.1016/0014-2999(93)90201-R
Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother 2006;40:2187-94. DOI: https://doi.org/10.1345/aph.1H121
Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new nonpurine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 2005;12:22-34. DOI: https://doi.org/10.1097/00045391-200501000-00005

How to Cite

Di Zio, I., & Cisternino, R. (2024). A rare case of thrombocytopenia secondary to taking febuxostat. Italian Journal of Medicine, 18(2). https://doi.org/10.4081/itjm.2024.1724
Copyright (c) 2024 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.